The COO appointment and segment restructuring signal a proactive operational response to the cybersecurity disruption, but the financial impact is still unfolding. Watch for the Q3 2026 earnings call on Oct 28, 2026, where management will provide updated guidance incorporating the incident's impact.
Price Chart
Executive Summary
Boston Scientific announced the promotion of Joe Fitzgerald to COO effective Jan 1, 2027, and a new three-segment operating structure (Interventional Therapies, Rhythm Solutions, MedSurg). Separately, the company appointed Mark Bickel as the new Chief Accounting Officer effective March 1, 2027. These organizational changes come just weeks after the company disclosed a material cybersecurity incident that will cause it to miss Q3 and FY2026 guidance, making this a restructuring/recovery play rather than a routine promotion.
Key Facts
- Joe Fitzgerald promoted to EVP and COO, effective Jan 1, 2027; base salary set at $1,050,000 with a 110% bonus target and a $7,000,000 equity grant.
- New operating structure creates three reportable segments: Interventional Therapies, Rhythm Solutions, and MedSurg, effective Jan 1, 2027.
- Mark Bickel appointed SVP, Global Accounting Controller and CAO, effective March 1, 2027, replacing Emily Woodworth who transitions to a new role.
- This filing follows a material cybersecurity incident (disclosed Aug 26, 2026) that caused a global operational disruption; the company expects to miss Q3 and FY2026 net sales growth and adjusted EPS guidance.
- The company states it does not expect the incident to have a material impact on long-term financial condition.
Financial Impact
Cybersecurity incident expected to cause a material impact on Q3 and FY2026 results; prior guidance for net sales growth and adjusted EPS will not be met. No specific dollar amounts provided.
Risk Factors
- Cybersecurity incident may have lingering operational and financial effects beyond current estimates.
- Restructuring execution risk — new COO and segment structure may cause near-term organizational friction.
- Potential for further negative guidance revisions if operational recovery takes longer than expected.
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0000885725-26-000064 |
| Exhibit: ex991-octoberbscpressrelea.htm | 0000885725-26-000064 |
| Exhibit: ex101-offerletter.htm | 0000885725-26-000064 |
| Document: 0000885725-26-000064-index-headers.html | 0000885725-26-000064 |
| Document: 0000885725-26-000064-index.html | 0000885725-26-000064 |
| Document: 0000885725-26-000064.txt | 0000885725-26-000064 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 23, 2026 4d ago | Institutional Cluster | $45.69 $45.58 | ▲ +0.24% | ▲ +0.95% | $45.06 (+1.38%) |
Oct 7, 2026 20d ago | 8-K | $41.58 $42.04 | ▲ +1.11% | ▲ +1.53% | $45.06 (+8.37%) |
Sep 23, 2026 4w ago | 8-K | $44.62 $44.68 | ▼ −0.13% | ▼ −0.22% | $45.06 (−0.99%) |
Aug 31, 2026 8w ago | Court Ruling | $48.08 $48.37 | ▲ +0.60% | ▲ +0.16% | $45.06 (−6.28%) |
Aug 26, 2026 8w ago | 8-K | $48.17 $46.67 | ▲ +3.11% | ▲ +3.77% | $45.06 (+6.46%) |
Aug 22, 2026 9w ago | Institutional Cluster | $49.01 $49.86 | ▲ +1.73% | ▲ +1.41% | $45.06 (−8.06%) |
Aug 7, 2026 11w ago | Insider Cluster | $50.46 $51.19 | ▲ +1.45% | ▲ +1.77% | $45.06 (−10.70%) |
Aug 7, 2026 11w ago | Insider Cluster | $50.46 $51.19 | ▲ +1.45% | ▲ +1.77% | $45.06 (−10.70%) |
Aug 5, 2026 11w ago | Insider Cluster | $49.30 $49.31 | ▲ +0.02% | ▼ −0.59% | $45.06 (−8.60%) |
Jul 29, 2026 12w ago | 8-K | $46.04 $46.00 | ▲ +0.09% | ▲ +1.76% | $45.06 (+2.13%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers